c-Kit

Elenestinib phosphate is an orally active tyrosine kinase inhibitor that selectively targets the KIT D816V mutation, exhibiting an IC50 of 0.2 nM. This compound's targeted inhibition is particularly relevant for studying systemic mastocytosis, as it provides insights into the role of mutated KIT in this condition. Notably, elenestinib phosphate has limited capacity to penetrate the blood-brain barrier, making it suitable for investigating its effects in peripheral tissues.

KBP-7018 is a selective tyrosine kinase inhibitor targeting c-KIT, PDGFR, and RET. It demonstrates potent inhibition with IC50 values of 10 nM for c-KIT, 7.6 nM for PDGFR, and 25 nM for RET. This compound is valuable for investigating the molecular mechanisms and potential treatments related to idiopathic pulmonary fibrosis.

c-Kit-IN-7 is a potent c-Kit inhibitor that demonstrates an IC50 of ≤10 nM. It effectively inhibits cell proliferation in GIST430 and BaF3 mutant cell lines, with IC50 values of ≤100 nM. This compound is crucial for research focused on cancers driven by c-KIT kinase mutations, providing valuable insights into therapeutic strategies targeting this pathway.

PLX647 dihydrochloride is a potent and selective dual inhibitor of FMS and KIT kinases, exhibiting IC50 values of 28 nM and 16 nM, respectively. This compound demonstrates high selectivity for FMS and KIT over a broad spectrum of 400 kinases at a concentration of 1 μM, with minimal activity against FLT3 and KDR (IC50s of 91 nM and 130 nM, respectively). PLX647 dihydrochloride is valuable for research applications focused on hematopoietic and oncogenic signaling pathways.

c-Kit-IN-14 is a selective inhibitor of the c-Kit kinase, effectively blocking its phosphorylation with an IC50 of 0.4 nM for pKIT. It demonstrates potent activity against Exon 11 c-Kit mutations, also with an IC50 of 0.4 nM. This compound is primarily utilized in research related to mast cell-mediated disorders, including urticaria, providing insights into therapeutic strategies targeting c-Kit signaling pathways.

c-Kit-IN-13 is a highly selective c-kit kinase inhibitor that effectively blocks the autophosphorylation of wild-type c-kit, demonstrating an IC50 of 0.3 nM for pKIT and 0.9 nM for Exon 11 KIT. This compound is particularly useful in researching mast cell-mediated conditions, including urticaria, providing insights into the role of c-kit in these pathologies. Its potent inhibitory activity makes it a valuable tool for studies focused on targeted therapies in hematological cancers and related disorders.

KBP-7018 hydrochloride is a selective inhibitor of tyrosine kinases, specifically targeting c-KIT, PDGFR, and RET. It exhibits significant inhibitory potency, with IC50 values of 10 nM, 7.6 nM, and 25 nM, respectively. This compound is utilized in research focused on idiopathic pulmonary fibrosis, facilitating investigations into pathways associated with this condition.

APcK110 is a potent inhibitor of the Kit receptor tyrosine kinase, with applications in the study of acute myeloid leukemia (AML). This compound has been shown to induce apoptosis in AML cells, offering valuable insights into therapeutic strategies for targeting this malignancy. Researchers can utilize APcK110 to explore mechanisms of resistance, cell signaling pathways, and potential combination therapies in AML treatment.

KI-328 is a selective inhibitor of the c-Kit kinase, specifically designed to target various mutant forms associated with acute myeloid leukemia (AML). It demonstrates effective inhibition of both wild-type and certain mutant KIT-expressing cell lines, although it shows diminished activity against the D816V-KIT variant. Comparative analyses with other potent KIT inhibitors indicate varying degrees of efficacy across different mutant forms, highlighting the necessity for targeted assessments in clinical applications. KI-328 provides a valuable tool for research focused on the biological mechanisms of KIT mutations and their implications in leukemia therapies.

c-Kit-IN-11 is a selective inhibitor of c-Kit, exhibiting an IC50 of 76 nM in Mo7e cells. This compound is valuable in research related to inflammatory conditions such as asthma, as well as in the study of malignant cancers. Its targeted inhibition of c-Kit makes it a useful tool for investigating the underlying mechanisms of these diseases and potential therapeutic strategies.

GW694590A is an inhibitor targeting firefly luciferase (Fluc) that enhances the stability of the MYC protein, subsequently increasing its endogenous levels. This compound also inhibits receptor tyrosine kinases, demonstrating significant reductions in DDR2, KIT, and PDGFRα activity at 1 μM. GW694590A serves as a versatile protein kinase inhibitor, influencing both ATP-dependent and -independent luciferase systems, making it valuable for studies in cellular signaling and gene expression regulation.

c-Kit-IN-8 is a selective inhibitor of the c-Kit kinase, demonstrating high efficacy with an IC50 greater than 1 μM for uKIT kinase. It effectively reduces the proliferation of cancer cells, including GIST430 and BaF3 cell lines, with an IC50 of over 0.1 μM. This compound is valuable for research in cancer biology, particularly in studies focusing on c-Kit-related signaling pathways and therapeutic resistance in oncogenesis.

c-Kit-IN-10 is a selective inhibitor of the c-Kit receptor tyrosine kinase, which plays a critical role in hematopoiesis, cell signaling, and tumorigenesis. This compound demonstrates potent anti-proliferative activity against c-Kit-dependent cancers and has potential applications in the study of inflammatory conditions such as asthma. Researchers may utilize c-Kit-IN-10 to investigate its therapeutic effect on disease models characterized by aberrant c-Kit signaling.

Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.

Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors.

MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.

OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret.

Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl.

Chiauranib (CS2164) is an orally active, multi-targeted small molecule inhibitor with potent anticancer activity. It targets key kinases involved in tumor angiogenesis, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as mitosis-related kinase Aurora B and inflammation-associated kinase CSF-1R. Chiauranib exhibits IC₅₀ values ranging from 1 to 9 nM against these targets. Through simultaneous inhibition of angiogenesis, cell division, and inflammation pathways, Chiauranib exerts strong antitumor effects and is a promising candidate for the treatment of various solid tumors.

Pexidartinib hydrochloride is a potent, orally active inhibitor of the colony stimulating factor 1 receptor (CSF1R) and c-Kit, demonstrating ATP-competitive activity with IC50 values of 20 nM and 10 nM, respectively. This compound exhibits selective inhibition, with 10- to 100-fold potency over other related kinases. Pexidartinib hydrochloride promotes apoptosis in affected cells and exhibits significant anti-cancer properties, making it a valuable tool for research in oncology and immunology.